Phio Pharmaceuticals shares rise 11.48% intraday after positive 1b trial results for PH-762, showing 85% pathological response rate in highest dose group.

Phio Pharmaceuticals surged 11.48% intraday as the clinical-stage siRNA bio-pharma company reported positive phase 1b clinical trial results for its lead candidate PH-762, targeting skin cancer. The trial, announced on February 10, 2026, showed no serious adverse events or dose-limiting toxicities, with an 85% pathological response rate in the highest dose group of 22 patients. The company develops cancer therapies using its INTASYL gene-silencing platform, focusing on advancing end-to-end siRNA-based treatments for oncology indications.